Author: Safar, Hussain A.; Mustafa, Abu Salim; McHugh, Timothy D.
Title: COVID-19 vaccine development: What lessons can we learn from TB? Cord-id: vb7do3u3 Document date: 2020_11_30
ID: vb7do3u3
Snippet: At the time of writing, the SARS-CoV-2 virus has infected more than 49 million people causing more than 1.2 million deaths worldwide since its emergence from Wuhan, China in December 2019. Vaccine development against SARS-CoV-2 has drawn the global attention in order to stop the spread of the virus, with more than 10 vaccines being tested in phase III clinical trials, as of November 2020. However, critical to vaccine development is consideration of the immunological response elicited as well as
Document: At the time of writing, the SARS-CoV-2 virus has infected more than 49 million people causing more than 1.2 million deaths worldwide since its emergence from Wuhan, China in December 2019. Vaccine development against SARS-CoV-2 has drawn the global attention in order to stop the spread of the virus, with more than 10 vaccines being tested in phase III clinical trials, as of November 2020. However, critical to vaccine development is consideration of the immunological response elicited as well as biological features of the vaccine and both need to be evaluated thoroughly. Tuberculosis is also a major infectious respiratory disease of worldwide prevalence and the vaccine development for tuberculosis has been ongoing for decades. In this review, we highlight some of the common features, challenges and complications in tuberculosis vaccine development, which may also be relevant for, and inform, COVID-19 vaccine development.
Search related documents:
Co phrase search for related documents- active disease and adequate immune response: 1
- active disease and low incidence: 1, 2
- active disease and macrophage activation: 1, 2, 3, 4
- active disease and macrophage monocyte: 1
- acute ards respiratory distress syndrome and ade antibody dependent enhancement: 1, 2
- acute ards respiratory distress syndrome and adequate immune response: 1
- acute ards respiratory distress syndrome and local inflammatory response: 1, 2, 3, 4
- acute ards respiratory distress syndrome and low incidence: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
- acute ards respiratory distress syndrome and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute ards respiratory distress syndrome and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- ade antibody dependent enhancement and adjuvant type: 1
Co phrase search for related documents, hyperlinks ordered by date